Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma

This study is testing a combination of two checkpoint immunotherapy drugs (lparomlimab and tuvonralimab) together with a procedure called TACE (which delivers chemotherapy directly into liver tumors via a blood vessel) and a targeted drug (lenvatinib) for people with advanced liver cancer (hepatocellular carcinoma) whose disease got worse after prior immunotherapy plus bevacizumab. **You may be eligible if...** - You are 18 or older - You have confirmed liver cancer (hepatocellular carcinoma) - Your cancer progressed or you could not tolerate prior treatment with a PD-1 blocker plus bevacizumab - You have at least one measurable tumor - Your liver is functioning reasonably well (Child-Pugh A or B, score ≤7) - Your life expectancy is at least 3 months - Active hepatitis B or C is being treated with antiviral medication **You may NOT be eligible if...** - You have had a liver transplant or are on a transplant list - You have cancer that has spread to the brain - You have severe portal vein tumor blockage (Vp4) - You have serious uncontrolled high blood pressure, heart disease, or heart failure - You have bleeding tendencies or had a stroke in the past 12 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.